Verzenio
FY2025 revenue $5.72B, up 8% vs FY2024.
The numbers
Revenue$5,723MFY2025 · +8% vs FY2024 ($5,307M) · source ↗
What it is
Oncology drug for breast cancer, reported as a separate product line in Lilly's 2025 revenue table.
Why it matters to the stock. Verzenio is the third-largest named Lilly product by 2025 revenue and a steadier contributor than the obesity franchise.
News
No stories tagged to this project yet.